TriaGen Wealth Management LLC Purchases New Stake in Humana Inc. $HUM

TriaGen Wealth Management LLC acquired a new stake in shares of Humana Inc. (NYSE:HUM) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 3,039 shares of the insurance provider’s stock, valued at approximately $1,207,000.

Other hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in shares of Humana by 0.7% during the fourth quarter. Vanguard Group Inc. now owns 14,261,860 shares of the insurance provider’s stock worth $3,652,890,000 after purchasing an additional 106,030 shares during the last quarter. Capital International Investors increased its holdings in Humana by 113.9% in the fourth quarter. Capital International Investors now owns 5,818,008 shares of the insurance provider’s stock valued at $1,490,239,000 after buying an additional 3,097,571 shares during the last quarter. Pzena Investment Management LLC raised its stake in Humana by 34.3% during the first quarter. Pzena Investment Management LLC now owns 5,470,982 shares of the insurance provider’s stock valued at $948,614,000 after buying an additional 1,398,774 shares in the last quarter. State Street Corp lifted its holdings in Humana by 1.8% during the 4th quarter. State Street Corp now owns 5,462,549 shares of the insurance provider’s stock worth $1,403,877,000 after buying an additional 97,211 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Humana by 0.8% during the 4th quarter. Geode Capital Management LLC now owns 3,184,569 shares of the insurance provider’s stock worth $812,540,000 after buying an additional 23,732 shares during the last quarter. 92.38% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

HUM has been the subject of a number of research analyst reports. HSBC downgraded Humana to a “hold” rating in a report on Thursday, July 30th. Leerink Partners raised shares of Humana from a “market perform” rating to an “outperform” rating and set a $513.00 price objective for the company in a report on Thursday, July 30th. Cantor Fitzgerald increased their target price on shares of Humana from $264.00 to $300.00 and gave the stock a “neutral” rating in a report on Tuesday, July 7th. TD Cowen raised their price target on shares of Humana from $350.00 to $370.00 and gave the stock a “hold” rating in a research report on Friday, July 31st. Finally, JPMorgan Chase & Co. lifted their price target on shares of Humana from $316.00 to $393.00 and gave the company a “neutral” rating in a report on Monday. Fourteen investment analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Humana presently has a consensus rating of “Hold” and a consensus target price of $395.22.

Humana News Summary

Here are the key news stories impacting Humana this week:

• Positive Sentiment: Higher earnings outlook: Zacks Research raised its Q1 2027 EPS estimate to $9.04 from $8.70, suggesting improved expectations for Humana’s near-term profitability. The firm nonetheless maintained a Hold rating. Humana earnings estimate article
• Positive Sentiment: Medicaid and underserved-member expansion: Humana is partnering with Cityblock Health to support low-income and dual-eligible Medicare Advantage members. The move could strengthen care coordination and support growth in Medicaid and Medicare-related services. Humana Cityblock partnership article
• Positive Sentiment: Caregiver-retention initiative: A HealthStream agreement will fund 1,000 caregiver scholarships and provide recruitment and retention tools in Indiana, potentially supporting staffing at Humana’s CenterWell operations. Humana HealthStream deal article
• Positive Sentiment: Brokerage price-target support: JPMorgan raised its price target for HUM to $393, indicating modest upside relative to the referenced trading level. JPMorgan Humana price target article
• Neutral Sentiment: Leadership change: Humana appointed James Holland as president of its Medicaid business, underscoring the company’s focus on Medicaid but creating an execution milestone for investors. Humana Medicaid leadership article
• Neutral Sentiment: Legal proceeding: Humana agreed not to reference Teva’s Israeli identity during an upcoming U.S. drug-price-fixing trial. The agreement is procedural and does not indicate a new financial liability for Humana. Humana Teva trial article
• Negative Sentiment: Medicare Advantage membership reduction: Humana reportedly plans to drop approximately 600,000 Medicare Advantage members in 2027. Although the move may improve plan economics, investors may view the lost membership and related revenue as a near-term headwind. Humana Medicare Advantage membership article
• Negative Sentiment: More cautious rating: Zacks Research downgraded Humana from Strong Buy to Hold, limiting the positive impact from the firm’s higher EPS forecast. Zacks Humana rating

Humana Trading Down 1.1%

Shares of NYSE HUM opened at $384.50 on Friday. Humana Inc. has a 12-month low of $163.11 and a 12-month high of $428.88. The company has a market cap of $46.17 billion, a price-to-earnings ratio of 36.38, a price-to-earnings-growth ratio of 2.22 and a beta of 0.72. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.62. The stock’s 50 day simple moving average is $381.25 and its 200 day simple moving average is $274.88.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, July 29th. The insurance provider reported $7.61 EPS for the quarter, topping analysts’ consensus estimates of $7.27 by $0.34. The firm had revenue of $40.89 billion during the quarter, compared to the consensus estimate of $40.58 billion. Humana had a return on equity of 11.20% and a net margin of 0.88%.The firm’s revenue was up 26.2% on a year-over-year basis. During the same period in the prior year, the business earned $6.27 EPS. Equities research analysts expect that Humana Inc. will post 9.09 EPS for the current year.

About Humana

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.